Synapse - Michael Mauro

Results (272)

Sustained efficacy and safety with asciminib (ASC) after almost 4 years of median follow-up from ASCEMBL, a phase 3 study of ASC vs bosutinib (BOS) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after ≥2 prior tyrosine kinase inhibitors (TKIs): An end of study treatment (EOS Tx) update, including results from switch population

Meeting Abstract

Mauro, M.; Minami, Y.; Hochhaus, A.; Lomaia, E.; Voloshin, S.; Turkina, A.; Kim, D. W.; Apperley, J. F.; Cortes, J.; Abdo, A. N. R.; more...
Blood (2023)

Fulltext@MSK | Save

HJKC3-0006: Outcome of patients with CML treated on second line or later therapy in routine clinical practice

Meeting Abstract

Thompson, J. E.; Gao, Y.; Visotcky, A.; Flynn, K. E.; Mauro, M.; Giever, E.; Baim, A.; Akinola, I.; Larson, R.; Jamy, O.; more...
Blood (2023)

Fulltext@MSK | Save

HJKC3-007: Outcomes of patients with chronic myeloid leukemia in chronic phase treated with asciminib and other tyrosine kinase inhibitors in routine clinical practice

Meeting Abstract

Mauro, M.; Atallah, E. L.; Thompson, J. E.; Gao, Y.; Visotcky, A.; Giever, E.; Baim, A.; Akinola, I.; Larson, R. A.; Jamy, O.; more...
Blood (2023)

Fulltext@MSK | Save

Long-term results from the OPTIC trial: A dose-optimization study of 3 starting doses of ponatinib

Meeting Abstract

Cortes, J.; Deininger, M.; Lomaia, E.; Moiraghi, B.; Undurraga, S.; Pavlovsky, C.; Chuah, C.; Sacha, T.; Lipton, J. H.; McCloskey, J.; more...
Blood (2023)

Fulltext@MSK | Save

ASC2ESCALATE: A US phase 2, open-label, single-arm, dose-escalation study of asciminib (ASC) monotherapy in patients (Pts) with chronic myeloid leukemia in chronic phase (CML-CP) as second-line (2L) and first-line (1L) treatment

Meeting Abstract

Atallah, E. L.; Mauro, M.; Sasaki, K.; Levy, M.; Koller, P. B.; Yang, D.; Laine, D.; Sabo, J.; Gu, E.; Cortes, J.
Blood (2023)

Fulltext@MSK | Save

A phase I study of ruxolitinib in combination with abemaciclib for patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis

Meeting Abstract

Bewersdorf, J. P.; Derkach, A.; Masarova, L.; Pemmaraju, N.; Stein, E. M.; Mauro, M.; Rampal, R. K.; Bose, P.
Blood (2023)

Fulltext@MSK | Save

With up to 8 years of therapy, asciminib (ASC) monotherapy demonstrated continued favorable efficacy, safety, and tolerability in patients (pts) with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) without the T315I mutation: Final results from the phase 1 x2101 study

Meeting Abstract

Hochhaus, A.; Kim, D. W.; Cortes, J.; Sasaki, K.; Mauro, M.; Hughes, T. P.; Breccia, M.; Talpaz, M.; Minami, H.; Goh, Y. T.; more...
Blood (2023)

Fulltext@MSK | Save

Asciminib (ASC) in combination with Imatinib (IMA), nilotinib (NIL), or dasatinib (DAS) may be a potential treatment (Tx) option in patients (pts) with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase or accelerated phase (Ph + CML-CP/AP): Final results from the asciminib phase 1 study

Meeting Abstract

Cortes, J.; Lang, F.; Rea, D.; Hochhaus, A.; Breccia, M.; Goh, Y. T.; Heinrich, M. C.; Hughes, T. P.; Janssen, J. J. W. M.; le Coutre, P.; more...
Blood (2023)

Fulltext@MSK | Save

Impact of mutations in blood cancer-related genes on clinical outcomes in chronic myeloid leukemia in chronic phase (CML-CP) after ≥2 tyrosine kinase inhibitors ( TKIs) in the Ascembl trial